COSM - Virax stock rises on contract with Cosmos to market COVID Influenza combo rapid test
- Virax Biolabs ( NASDAQ: VRAX ) said it signed a purchase order with Cosmos Health ( NASDAQ: COSM ) to launch and market COVID-19 and Influenza A+B antigen combo rapid detection kits.
- Under a previously signed distribution agreement in September 2022, Cosmos will have exclusive distribution rights for Greece and Cyprus, with the opportunity to distribute ViraxClear branded test kits across Europe on a non-exclusive basis.
- The combo test is a single-use test kit for qualitative detection of nucleocapsid protein antigen of Influenza A and B viral antigens and COVID-19 antigen from nasal swab specimens.
- "We are pleased to offer a dual solution, that can accurately identify infections related to these viruses, with results typically available in 15 minutes," said Virax's Chairman and CEO James Foster.
- VRAX +8.31% to $0.89 premarket Feb. 7
- COSM +1.32% to $5.38 premarket to $5.57
For further details see:
Virax stock rises on contract with Cosmos to market COVID, Influenza combo rapid test